Hemalini Mehta, MD

Clinical Research Institute, Minneapolis, MN, USA

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-711) Persistence of Immunogenicity and Safety of the Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) Administered to Adults 50–59 Years of Age (YOA)
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT